IL264425B2 - t cell receptors against kras-g20 - Google Patents
t cell receptors against kras-g20Info
- Publication number
- IL264425B2 IL264425B2 IL264425A IL26442519A IL264425B2 IL 264425 B2 IL264425 B2 IL 264425B2 IL 264425 A IL264425 A IL 264425A IL 26442519 A IL26442519 A IL 26442519A IL 264425 B2 IL264425 B2 IL 264425B2
- Authority
- IL
- Israel
- Prior art keywords
- seq
- amino acid
- acid sequence
- tcr
- nos
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264425A IL264425A (enExample) | 2019-03-31 |
| IL264425B1 IL264425B1 (en) | 2023-05-01 |
| IL264425B2 true IL264425B2 (en) | 2023-09-01 |
Family
ID=59564253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264425A IL264425B2 (en) | 2016-08-02 | 2017-07-31 | t cell receptors against kras-g20 |
| IL301894A IL301894B2 (en) | 2016-08-02 | 2017-07-31 | Anti-KRAS-G20 T-cell receptors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301894A IL301894B2 (en) | 2016-08-02 | 2017-07-31 | Anti-KRAS-G20 T-cell receptors |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10611816B2 (enExample) |
| EP (2) | EP4159751A1 (enExample) |
| JP (4) | JP6993402B2 (enExample) |
| KR (1) | KR102527052B1 (enExample) |
| CN (2) | CN109790211B (enExample) |
| AU (2) | AU2017306038B2 (enExample) |
| CA (1) | CA3032870A1 (enExample) |
| DK (1) | DK3494133T3 (enExample) |
| ES (1) | ES2928051T3 (enExample) |
| HR (1) | HRP20221183T1 (enExample) |
| HU (1) | HUE060121T2 (enExample) |
| IL (2) | IL264425B2 (enExample) |
| LT (1) | LT3494133T (enExample) |
| PL (1) | PL3494133T3 (enExample) |
| PT (1) | PT3494133T (enExample) |
| RS (1) | RS63615B1 (enExample) |
| SG (2) | SG10201913959WA (enExample) |
| SI (1) | SI3494133T1 (enExample) |
| SM (1) | SMT202200379T1 (enExample) |
| WO (1) | WO2018026691A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017306038B2 (en) * | 2016-08-02 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-KRAS-G12D T cell receptors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| JP7256794B2 (ja) | 2017-09-20 | 2023-04-12 | アメリカ合衆国 | 変異型ｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 |
| FI3692140T3 (fi) | 2017-10-05 | 2023-10-11 | Us Health | Menetelmiä solujen laajentamiseksi selektiivisesti ekspressoiden TCR:ää vakiolla muriinialueella |
| US12246067B2 (en) | 2018-06-19 | 2025-03-11 | Biontech Us Inc. | Neoantigens and uses thereof |
| WO2020154617A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| CA3130618A1 (en) * | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| WO2021092223A1 (en) * | 2019-11-05 | 2021-05-14 | Board Of Regents, The University Of Texas System | Hla restricted hormad1 t cell receptors and uses thereof |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| JP7614659B2 (ja) * | 2019-12-30 | 2025-01-16 | ブリスター イムノテック リミテッド | 強化されたｔ細胞受容体ｓｔａｒ及びその用途 |
| EP4178976A1 (en) * | 2020-07-13 | 2023-05-17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class ii?restricted drb t cell receptors against ras with g12d mutation |
| GB2615010A (en) * | 2020-10-02 | 2023-07-26 | Us Health | HLA class II-restricted DQ T cell receptors against RAS with G13D mutation |
| AU2021381384A1 (en) * | 2020-11-20 | 2023-06-22 | Think Therapeutics, Inc. | Compositions and methods for optimized peptide vaccines |
| AU2021388167A1 (en) * | 2020-11-25 | 2023-07-06 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| KR20230150336A (ko) | 2021-02-25 | 2023-10-30 | 알로노스 테라퓨틱스 인코포레이티드 | 폴리시스트론 발현 카세트를 포함하는 재조합 벡터 및 이의 사용 방법 |
| EP4334361A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN119744173A (zh) * | 2022-07-22 | 2025-04-01 | 得克萨斯大学体系董事会 | 用于过继免疫疗法的具有增强功能的表达cd3的自然杀伤细胞 |
| CN115850444B (zh) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117777270B (zh) * | 2022-09-29 | 2025-04-25 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| EP4633665A2 (en) * | 2022-12-13 | 2025-10-22 | BioNTech US Inc. | T cell receptor constructs and uses thereof |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN120157754A (zh) * | 2023-12-14 | 2025-06-17 | 新景智源生物科技(苏州)有限公司 | Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| ES2602145T3 (es) | 2002-09-06 | 2017-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa |
| CA2674445C (en) | 2007-01-12 | 2016-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| EP2618835B1 (en) | 2010-09-20 | 2017-07-05 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| CA2853645A1 (en) * | 2011-11-30 | 2013-06-06 | National Cancer Center | Induced malignant stem cells |
| KR20160013049A (ko) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| EP3223850B1 (en) | 2014-11-26 | 2020-01-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-mutated kras t cell receptors |
| US10556940B2 (en) | 2015-09-15 | 2020-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-Cw8 restricted mutated KRAS |
| AU2017306038B2 (en) * | 2016-08-02 | 2023-06-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-KRAS-G12D T cell receptors |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
-
2017
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en not_active Ceased
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 CA CA3032870A patent/CA3032870A1/en active Pending
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 SM SM20220379T patent/SMT202200379T1/it unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active Active
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 IL IL301894A patent/IL301894B2/en unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125B2/en active Active
- 2023-12-27 JP JP2023221526A patent/JP7649370B2/ja active Active
-
2024
- 2024-01-25 US US18/423,020 patent/US12391742B2/en active Active
-
2025
- 2025-03-07 JP JP2025036871A patent/JP2025090690A/ja active Pending
- 2025-07-15 US US19/269,450 patent/US20250340611A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12391742B2 (en) | Anti-KRAS-G12D T cell receptors | |
| EP3350213B1 (en) | T cell receptors recognizing hla-cw8 restricted mutated kras | |
| AU2017258745A1 (en) | Anti-KK-LC-1 T cell receptors | |
| HK40009637B (en) | Anti-kras-g12d t cell receptors | |
| HK40009637A (en) | Anti-kras-g12d t cell receptors | |
| CA2998869C (en) | T cell receptors recognizing hla-cw8 restricted mutated kras | |
| HK40008470A (en) | Anti-kras-g12d t cell receptors | |
| HK40008470B (zh) | 抗kras-g12d t细胞受体 | |
| HK1257902B (en) | T cell receptors recognizing hla-cw8 restricted mutated kras |